LeapFrog Investments said this week it has raised more than $1 billion in a new investment fund that targets high-impact health and financial-services

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.

Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.

There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth.

Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer’s. However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such as Annovis Bio Inc. (NYSE: ANVS) ( profile ), there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications. Broadly speaking, there is ample reason to be bullish on new treatments for a variety of significant diseases, including AD and obesity, as companies such as Eli Lilly (NYSE: LLY) , Pfizer Inc. (NYSE: PFE) , Novo Nordisk (NYSE: NVO) and AbbVie Inc. (NASDAQ: ABBV) are making investments and progress on historically…

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END

PALM BEACH, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by incorporating aversive agents into transdermal patches. Abuse-deterrent opioid formulations (ADFs) are designed to make it more difficult to abuse opioids by making them less attractive or rewarding, or by increasing the difficulty of manipulating them. ADFs can help reduce the risk of adverse effects associated with snorting or injecting opioids, and may also help prevent medication errors. Active companies in the industry include: Nutriband Inc. (NASDAQ: NTRB), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Eli Lilly and Company (NYSE: LLY), Novartis AG (NYSE: NVS), Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX).

Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr....

Toronto, Ontario--(Newsfile Corp. - September 11, 2024) - Michael Kovacs, President and CEO, Harvest ETFs, ("Harvest" or the "Company") and...

Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last

Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and...

Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.

Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,

Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings

Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide.

Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in.

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of Alzheimer’s disease.

Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.